Methods of transplanting chondrocytes

• US 10,179,193 B2
• Filed: 01/16/2018
• Issued: 01/15/2019
• Est. Priority Date: 10/29/2012
• Status: Active Grant

• Current Assignee: Scripps Health
• Original Assignee: Scripps Health
• Inventors: D'Lima, Darryl D., Olee, Tsaiwei, Colwell, Clifford W.
• Primary Examiner(s): Visone, Thomas J.
• Application Number:
  US15/872,667
• Publication Number:
  US 20180154046A1
• Time in Patent Office: 364 Days
• Field of Search: None
• CPC Class Codes: A61L 2300/412 Tissue-regenerating or healing or proliferative agents
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 2430/02 for reconstruction of bones; weight-bearing implants
• CPC Class Codes: A61L 2430/06 for cartilage reconstruction, e.g. meniscus
• CPC Class Codes: A61L 27/26 Mixtures of macromolecular compounds
• CPC Class Codes: A61L 27/3817 Cartilage-forming cells, e.g. pre-chondrocytes
• CPC Class Codes: A61L 27/3821 Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
• CPC Class Codes: A61L 27/44 having a macromolecular matrix
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: C08L 5/08 Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
• CPC Class Codes: C08L 89/06 derived from leather or skin , e.g. gelatin

Abstract

Provided are tri-component matrices having collagen, hyaluronan, and chondroitin sulfate. Also provided are processes for producing a tri-component matrix. Additionally, provided are processes for providing cells capable of producing cartilage to a bone or cartilage defects.

Claims

1. A method of treating a bone or cartilage defect in a subject in need thereof, comprising administering a transplantation composition at a site of the bone or cartilage defect, the transplantation composition comprising:

a) a tri-component matrix, consisting of;

i) isolated and purified non-denatured type II collagen at a concentration of 0.5 mg/ml to 5 mg/ml;

ii) hyaluronan at a concentration of 1 mg/ml to 3 mg/ml; and

iii) chondroitin sulfate at a concentration of 0.25 mg/ml to 3 mg/ml; and

b) water; and

c) a population of cells.

2. The method of claim 1, wherein the population of cells comprises chondrocytes, chondroprogenitor cells, induced pluripotent stem cells, mesenchymal stem cells, osteoblasts, osteoprogenitors, or combinations thereof.

3. The method of claim 1, wherein new tissue is produced.

4. The method of claim 3, wherein the new tissue restores a surface of the cartilage or bone.

5. The method of claim 3, wherein the new tissue comprises collagen type II.

6. The method of claim 3, wherein the new tissue comprises superficial, intermediate, and deep zones characteristic of normal articular cartilage.

7. The method of claim 3, wherein the new tissue does not comprise teratomas, neoplastic cells, evidence of deformation, abnormal architectural features, or other inappropriate cell types.

8. The method of claim 1, wherein the population of cells comprises chondrocytes.

9. The method of claim 1, wherein the population of cells comprises chondroprogenitor cells.

10. The method of claim 1, wherein the population of cells comprises induced pluripotent stem cells.

11. The method of claim 10, wherein the induced pluripotent stem cells are derived from chondrocytes.

12. The method of claim 9, wherein the chondroprogenitor cells are H9-derived chondroprogenitor cells.

13. The method of claim 8, wherein the chondrocytes are Sox-9 transduced chondrocytes.

14. The method of claim 1, wherein the bone or cartilage defect is associated with a cartilage-related disorder.

15. The method according to claim 14, wherein the cartilage-related disorder is articular cartilage trauma, meniscus injury, a chondrogenesis disorder, arthritis, chondropathy, chondrosarcoma, chondromalacia, polychondritis, relapsing polychondritis, slipped epiphysis, osteochondritis dissecans, chondrodysplasia, costochondritis, osteochondroma, spondylosis, osteochondrosis, Tietze syndrome, dermochondrocorneal dystrophy of Francois, epiphyseal dysplasia, carpotarsal osteochondromatosis, achondroplasia, chondrocalcinosis, genochondromatosis, chondroma, achondrogenesis, echondroma, hypochondroplasia, or Keutel syndrome.

16. The method of claim 15, wherein the cartilage-related disorder is arthritis.

17. The method of claim 16, wherein the arthritis occurs in a knee, finger, wrist, hip, spine, shoulder, elbow, toe, ankle, or neck of the subject.

18. The method of claim 1, wherein the population of cells does not comprise adult human bone marrow-derived mesenchymal stem cells.

19. The method of claim 1, wherein the transplantation composition is capable of being in a form of an injectable gel.

20. The method of claim 1, wherein the transplantation composition comprises fibrin.